Puma Biotechnology | PBYI - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
Esperion Therapeutics USD -307.93M 5.97M 2026-03
Exelixis USD 1.94B 225.57M 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Incyte USD 5.62B 455.37M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Moderna USD 7.41B 1.24B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Takeda JPY 7.77T 129.5B 2026-03
TG Therapeutics USD 583.13M 64.89M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03